Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - pemetrexed disodium - powder for solution for infusion - 100mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - isavuconazonium sulfate - powder for solution for infusion - 200mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - vancomycin hydrochloride - powder for solution for infusion - 500mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

seacross pharmaceuticals ltd - pemetrexed disodium - powder for solution for infusion - 100mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

seacross pharmaceuticals ltd - pemetrexed disodium - powder for solution for infusion - 500mg

Armenija - angleščina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - pemetrexed (pemetrexed disodium heptahydrate) - powder for concentrate for solution for infusion - 500mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - tedizolid phosphate - powder for solution for infusion - 200mg

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alglucosidase alfa, quantity: 52.5 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; mannitol; nitrogen - myozyme (alglucosidase alfa-rch) is indicated for the long-term treatment of patients with a confirmed diagnosis of pompe disease (acid alfa-glucosidase deficiency).

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - decitabine - powder for solution for infusion - 50mg

Izrael - angleščina - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - concentrate for solution for infusion - posaconazole 300 mg/vial - posaconazole - noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults :- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate f